*Departments of Pathology, †Ontario Cancer Institute, ‡Department of Biostatistics, §Division of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and ¶Departments of Laboratory Medicine and Pathobiology, ‖Medicine, University of Toronto, Ontario, Canada.
J Thorac Oncol. 2013 Nov;8(11):1371-7. doi: 10.1097/JTO.0b013e3182a46fe9.
Fibroblast growth factor receptor 1 (FGFR1) gene amplification was recently reported as a recurrent abnormality in 10% to 20% of primary lung squamous cell carcinomas (SqCCs), and has attracted significant interest as a potential therapeutic target. Limited data are available for its prognostic impact in early-stage SqCC.
Tissue microarrays containing 135 primary lung SqCCs and 58 matching lymph node metastases were tested by interphase fluorescence in situ hybridization for DNA copy number (CN) abnormalities at the 8p12 region including FGFR1.
FGFR1amplification was found in 18.2% (22 of 121 evaluable) of primary SqCC, using a definition of average copies of FGFR1 per cell of 5.0 or more. Concordance rate between primaries and matching lymph node metastases was 97.7% (43 of 44; 7 amplified and 37 nonamplified), with the only discordant case showing CN at approximately the dichotomous cutoff. Similarly, concordance between two separate lymph node metastases in each of 10 patients was 100% (1 amplified and 9 nonamplified). Using various CN cutoffs, we found no statistically significant association between FGFR1 CN abnormalities and patient age, sex, tumor grade, stage, smoking status, disease-free survival, cause-specific survival, or overall survival.
FGFR1 amplification is not prognostic in resected lung squamous cell carcinoma patients.
成纤维细胞生长因子受体 1（FGFR1）基因扩增最近被报道在 10%至 20%的原发性肺鳞状细胞癌（SqCC）中反复出现异常，并且作为潜在的治疗靶点引起了极大的关注。关于其在早期肺鳞状细胞癌中的预后影响的数据有限。
使用间期荧光原位杂交技术，对包含 135 例原发性肺 SqCC 和 58 例匹配的淋巴结转移的组织微阵列进行检测，以检测 8p12 区域（包括 FGFR1）的 DNA 拷贝数（CN）异常。
使用每个细胞 FGFR1 平均拷贝数为 5.0 或更高的定义，在 121 例可评估的原发性 SqCC 中发现 FGFR1 扩增率为 18.2%（22/121）。原发性肿瘤与匹配的淋巴结转移之间的一致性率为 97.7%（43/44；7 例扩增和 37 例非扩增），唯一不一致的病例显示 CN 接近二分截止值。同样，在 10 例患者的每例中，两个独立的淋巴结转移之间的一致性为 100%（1 例扩增和 9 例非扩增）。使用不同的 CN 截止值，我们没有发现 FGFR1 CN 异常与患者年龄、性别、肿瘤分级、分期、吸烟状况、无病生存率、疾病特异性生存率或总生存率之间存在统计学显著关联。
在接受切除的肺鳞状细胞癌患者中，FGFR1 扩增与预后无关。
